UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds UroGen Pharma Ltd.

Core Viewpoint - UroGen Pharma Ltd. is facing a securities fraud class action lawsuit alleging misrepresentations regarding the approval of its lead pipeline product, UGN-102, which may impact investor confidence and the company's market position [2][3]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the District of New Jersey on behalf of investors who purchased UroGen securities between July 27, 2023, and May 15, 2025, alleging violations of the Securities Exchange Act of 1934 [2]. - Defendants in the lawsuit include UroGen and certain senior officers, accused of making false statements about the potential approval of the New Drug Application for UGN-102 [3]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiffs must file necessary documents by July 28, 2025, although participation as a lead plaintiff is not required to share in any potential recovery [4]. - All legal representation in this case operates on a contingency fee basis, meaning shareholders incur no fees or expenses unless there is a recovery [4]. Group 3: Law Firm Background - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for clients since 1993 and has a strong track record in class action litigation [5]. - The firm has been recognized multiple times in The National Law Journal's "Plaintiffs' Hot List" and has been listed in The Legal 500 for sixteen consecutive years, indicating a reputable standing in the legal community [5].